Emcure Pharmaceuticals Ltd.
NSE: EMCURE
Prev Close
1521.1
Open Price
1520
Volume
871,597
Today Low / High
1510.5 / 1585.6
52 WK Low / High
889 / 1585.6
Range
1,489 - 1,646
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 1567.8, with a change of 46.7 (3.07015%). The expected target range on the NSE is between 1,489 - 1,646. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Emcure Pharmaceuticals Ltd. Graph
Emcure Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Emcure Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,567.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,567.80 | 1,583.48 | 1,425.13 - 1,741.83 |
| 1,599.16 | 1,279.32 - 1,918.99 | ||
| 1,614.83 | 1,130.38 - 2,099.28 | ||
| Bearish Scenario | 1,567.80 | 1,552.12 | 1,396.91 - 1,707.33 |
| 1,536.44 | 1,229.16 - 1,843.73 | ||
| 1,520.77 | 1,064.54 - 1,977.00 |
Overview of Emcure Pharmaceuticals Ltd.
ISIN
INE168P01015
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
173,857
Market Cap
273,989,192,062
Last Dividend
3
Official Website
IPO Date
2024-07-10
DCF Diff
1,130.90
DCF
314
Financial Ratios Every Investor Needs
Stock Dividend of EMCURE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-14 | August 14, 25 | 3 | 3 | 2025-08-14 | 2025-09-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 7,808.27 Cr | 63.91 Cr | 27.51 Cr | 0.0035 | 0.00 Cr | 244.86 Cr | 1,084.73 Cr | 681.33 Cr | 0.43 | 1,495.49 Cr | 0.0873 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 121.82 Cr | 8,232.72 Cr | 3,591.17 Cr | 4,446.1860 Cr | 1,022.75 Cr | 900.93 Cr | 1,931.81 Cr | 2,444.05 Cr | 0.00 Cr | 14.49 Cr | 0.26 Cr | 2,668.2710 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 851.7050 Cr | -94.0010 Cr | -813.9570 Cr | 444.7780 Cr | -58.3020 Cr | -14.3110 Cr | -221.7670 Cr | 971.3490 Cr | -16.4346 Cr | 0.0000 Cr | -406.7120 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 2,363.48 Cr | 1,454.44 Cr | 909.04 Cr | 0.3846 | 355.44 Cr | 230.54 Cr | 12.16 | 456.45 Cr | 0.0975 |
| 2025-09-30 | 2,269.82 Cr | 889.53 Cr | 1,380.29 Cr | 0.6081 | 334.48 Cr | 243.46 Cr | 12.85 | 478.60 Cr | 0.1073 |
| 2025-06-30 | 2,100.54 Cr | 802.01 Cr | 1,298.52 Cr | 0.6182 | 304.43 Cr | 206.95 Cr | 10.92 | 416.97 Cr | 0.0985 |
| 2025-03-31 | 2,028.52 Cr | 1,067.77 Cr | 960.75 Cr | 0.4736 | 293.09 Cr | 188.96 Cr | 0.00 | 360.70 Cr | 0.0932 |
| 2024-12-31 | 1,962.63 Cr | 782.73 Cr | 1,179.90 Cr | 0.6012 | 264.94 Cr | 153.72 Cr | 8.12 | 358.50 Cr | 0.0783 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 472.25 Cr | 129.29 Cr | 601.54 Cr | 2,299.86 Cr | 2,304.58 Cr | 5,605.54 Cr | 2,439.79 Cr | 9,392.54 Cr | 4,508.51 Cr |
| 2025-03-31 | 121.82 Cr | 76.04 Cr | 197.87 Cr | 2,055.44 Cr | 1,931.81 Cr | 4,555.86 Cr | 2,444.05 Cr | 8,232.72 Cr | 3,591.17 Cr |
| 2024-09-30 | 162.08 Cr | 169.72 Cr | 331.80 Cr | 2,029.49 Cr | 1,751.59 Cr | 4,455.85 Cr | 2,380.66 Cr | 8,124.48 Cr | 3,821.15 Cr |
| 2024-03-31 | 108.96 Cr | 289.22 Cr | 398.17 Cr | 1,938.19 Cr | 1,525.10 Cr | 4,259.92 Cr | 2,411.26 Cr | 7,806.16 Cr | 4,684.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Gender: Not Specified
Year Born: 1952
Gender: male
Year Born: 1988
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1982
Gender: male
Year Born: 1967
Gender: male
Year Born: 1951
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born: 1976
Gender: female
Year Born: 1977
FAQs about Emcure Pharmaceuticals Ltd.
The CEO is Satish Ramanlal Mehta.
The current price is ₹1,445.30.
The range is ₹889-1585.6.
The market capitalization is ₹27,398.92 crores.
The dividend yield is 0.21%.
The P/E ratio is 31.50.
The company operates in the Healthcare sector.
Overview of Emcure Pharmaceuticals Ltd. (ISIN: INE168P01015) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹27,398.92 crores and an average daily volume of 173,857 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹3.